These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18451009)

  • 1. Lessons to take home from CATIE.
    Carpenter WT; Buchanan RW
    Psychiatr Serv; 2008 May; 59(5):523-5. PubMed ID: 18451009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.
    Tandon R; Belmaker RH; Gattaz WF; Lopez-Ibor JJ; Okasha A; Singh B; Stein DJ; Olie JP; Fleischhacker WW; Moeller HJ;
    Schizophr Res; 2008 Mar; 100(1-3):20-38. PubMed ID: 18243663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.
    Foussias G; Remington G
    Can J Psychiatry; 2010 Mar; 55(3):117-25. PubMed ID: 20370961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials.
    Lieberman JA
    J Clin Psychiatry; 2007 Feb; 68(2):e04. PubMed ID: 17335312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
    Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
    Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic safety and efficacy concerns.
    Meyer JM
    J Clin Psychiatry; 2007; 68 Suppl 14():20-6. PubMed ID: 18284274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation antipsychotics: cost-effectiveness, policy options, and political decision making.
    Rosenheck RA; Leslie DL; Doshi JA
    Psychiatr Serv; 2008 May; 59(5):515-20. PubMed ID: 18451007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
    J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation antipsychotics for schizophrenia: can we resolve the conflict?
    Leucht S; Kissling W; Davis JM
    Psychol Med; 2009 Oct; 39(10):1591-602. PubMed ID: 19335931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia.
    Park T; Kuntz KM
    Value Health; 2014 Jun; 17(4):310-9. PubMed ID: 24968989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Movement disorders induced by antipsychotic drugs: implications of the CATIE schizophrenia trial.
    Caroff SN; Hurford I; Lybrand J; Campbell EC
    Neurol Clin; 2011 Feb; 29(1):127-48, viii. PubMed ID: 21172575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.
    Rosenheck RA; Lieberman JA
    J Clin Psychiatry; 2007 Feb; 68(2):e05. PubMed ID: 17335313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New antipsychotic agents: emerging clinical profiles.
    Buckley PF
    J Clin Psychiatry; 1999; 60 Suppl 1():12-7; discussion 28-30. PubMed ID: 10037165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the effect of funding source in randomized clinical trials of second generation antipsychotics for the treatment of schizophrenia.
    Montgomery JH; Byerly M; Carmody T; Li B; Miller DR; Varghese F; Holland R
    Control Clin Trials; 2004 Dec; 25(6):598-612. PubMed ID: 15588746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atypical antipsychotics: mechanism of action.
    Seeman P
    Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems.
    Hamann J; Leucht S; Kissling W
    Pharmacopsychiatry; 2003 Jan; 36(1):18-26. PubMed ID: 12649770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.